Volume 7 Supplement 3

B cell targeted therapy: a new approach to the treatment of rheumatoid arthritis

Reviews

Edited by Larry Moreland

Supported by an educational grant from Genentech, Inc.

  1. Review

    Unmet needs in rheumatoid arthritis

    Until the pathophysiology/etiology of rheumatoid arthritis (RA) is better understood, treatment strategies must focus on disease management. Early diagnosis and treatment with disease-modifying antirheumatic d...

    Larry Moreland

    Arthritis Research & Therapy 2005 7(Suppl 3):S2

    Published on: 18 May 2005

  2. Review

    B cells in rheumatoid synovitis

    In rheumatoid arthritis, T cells, B cells, macrophages, and dendritic cells invade the synovial membranes, establishing complex microstructures that promote inflammatory/tissue destructive lesions. B cell invo...

    Cornelia M Weyand, Thorsten M Seyler and Jörg J Goronzy

    Arthritis Research & Therapy 2005 7(Suppl 3):S9

    Published on: 18 May 2005

  3. Review

    B cell targeted therapies

    Although the precise pathogenesis of rheumatoid arthritis (RA) remains unclear, many cell populations, including monocytes, macrophages, endothelial cells, fibroblasts and B cells, participate in the inflammat...

    Edward Keystone

    Arthritis Research & Therapy 2005 7(Suppl 3):S13

    Published on: 18 May 2005

  4. Review

    B cell non-Hodgkin's lymphoma: rituximab safety experience

    A substantial body of data supports use of rituximab as first-line and maintenance therapy for the treatment of indolent non-Hodgkin's lymphoma. With 7 years of postmarketing surveillance experience and more t...

    Ann Mohrbacher

    Arthritis Research & Therapy 2005 7(Suppl 3):S19

    Published on: 18 May 2005